Understanding the Role of Lymphangiogenesis
Lymphatic vessels are involved in maintaining immune balance, tissue fluid regulation, and structural features within the endometrium. During the implantation window, lymphatic pathways are hypothesised to contribute to conditions associated with embryo attachment and early pregnancy biology.
For more than 15 years, LYMPHOGENiX has undertaken foundational research to investigate how targeted activation of lymphangiogenesis may support aspects of this biological environment in preclinical models. These studies explore whether modulation of lymphatic function in uterine tissue is associated with implantation-related biological markers and pathways; clinical relevance remains under investigation and has not been established.
The scientific insights from these investigations help inform the rationale for the Vessely™ preclinical research programme and related exploratory studies.
From Discovery to Translational Research
LYMPHOGENiX research encompasses discovery science, applied biology, and early preclinical development. The platform integrates cellular biology, immunology, and reproductive biology to translate fundamental insights into investigational programmes.
The current programme is progressing from mechanistic discovery toward planned large-animal translational studies designed to evaluate feasibility, dose selection, and biological response under controlled conditions. Large-animal studies are intended to generate translational evidence to inform future clinical planning, but their findings do not confirm clinical outcomes in humans. Progression to human studies remains contingent on additional evidence and regulatory approvals.
Peer-Reviewed Evidence Supporting the Biology
Key publications highlight the relationship between lymphatic vessel activation and successful implantation, establishing the biological rationale for therapeutic development.
Include links to LYMPHOGENiX-related work and selected external academic references that validate the role of lymphangiogenesis in reproductive health.
Please note that the infertility-related experimental data are currently confidential and will not be prepared for publication until the relevant patent application has been formally filed.
Circulation Journal (2026)
Therapeutic Lymphangiogenesis Using Induced Cardiac Fibroblasts Protects the Heart From Heart Failure With Preserved Ejection Fraction Progression by Exerting Anti-Inflammatory and Antifibrotic Effects
PLoS ONE (2020)
Human cardiac fibroblasts expressing VCAM1 improve heart function in postinfarct heart failure rat models by stimulating lymphangiogenesis
Scientific Reports (2025)
Adrenomedullin production by adult cardiac fibroblasts via NF-κB/STAT6 signaling enhances post-infarction lymphangiogenesis and cardiac repair
Protected Innovation
LYMPHOGENiX maintains a portfolio of international patents covering lymphangiogenic technologies, cell-based regenerative approaches, and analytical systems that support ongoing preclinical research and future development possibilities. This intellectual property provides a foundation for partnerships and licensing discussions.